A Phase 2/3 Study of Osivelotor in Adult and Adolescent Participants With SCD
← catalyst calendarNCT05431088 · readout in 1,594 d
Sponsored by Pfizer (industry) · PFE — their whole pipeline →.
Phase
Phase 2/3
Status
Recruiting
Study type
Interventional
Design
Randomized · Quadruple · Treatment
Enrollment
389estimated
Sites
80
Countries
Brazil, India, Kenya +4
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2022-09-22 | actual | When the study began enrolling |
| Primary completion | 2030-12-30 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2032-12-31 | estimated | The whole study's end, after follow-up |
| First posted | 2022-06-24 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-18 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Sickle Cell Disease
Intervention
- Drug: Osivelotor — also filed as PF-07940367 or GBT021601
Primary outcomes
what the primary-completion date above is the date OFPart A
measured Through week 12
Part B
measured Through week 48
OLE
measured Approximately 24 months after last patient enrolled
Publications
- PMID 40832524 — linked by the registry
- PMID 37254256 — linked by the registry
Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.
Permalink · PFE's whole pipeline · Catalyst calendar · Every registered study · What changed